Skip to main content

Table 3 Temporal trends of patient characteristics’ in patients with advanced CKD (G3b-G5)

From: Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry

  Time period
T1 2006–2010 (n = 407) T2 2011–2015 (n = 313) T3 2016–2019 (n = 298) Significance
Age (years ± SD) 74.5 ± 10 76.8 ± 12 76.6 ± 11 0.012
Women (%) 44.7 53.2 42.6 0.72
Body mass index (BMI) (kg/m2 ± SD) 27.5 ± 5 27.1 ± 5 26.9 ± 5 0.09
Diabetes (%) 32.0 29.0 27.4 0.15
Current smokers (%) 19.2 16.2 11.8  < 0.01
Arterial hypertension (%) 72.6 73.6 70.0 0.46
Treatment strategy
 Primary PCI (%) 75.8 88.8 90.3 < 0.01
 Urgent/early elect. CABG (%) 10.4 6.1 5.1 < 0.01
 Conservative (%) 13.8 5.1 4.7 < 0.01
Coronary vessels diseased
 1 (%) 19.3 26.7 19.5 0.79
 2 (%) 32.7 29.1 26.7 0.09
 3 (%) 48.1 44.1 53.8 0.2
Cardiogenic shock (%) 29.9 28.8 34.6 0.24
TIMI 0/1 flow after PCI (%) 11.1 10.8 9.8 0.56
Peak CK > 2000 U/l (%) 26.6 30.1 30.3 0.29
Contrast media used (ml ± SD) 132 ± 62 153 ± 76 152 ± 73 < 0.01
Contrast media > 150 ml (%) 27.7 43.0 41.6 < 0.01
Stent type in PCI cohort
 Bare metal stent (%) 88.3 42.8 0.3 < 0.01
 Drug eluting stent (%) 1.3 46.4 90.7 < 0.01
 No stent (POBA) (%) 10.4 10.7 8.9 0.52
No. of stents impl. (n ± SD) 1.3 ± 0.6 1.5 ± 0.8 1.8 ± 1.0  < 0.01
Medication at discharge
 ASS (%) 91.9 89.1 86.5 < 0.02
 Clopidogrel (%) 83.0 48.3 28.2 < 0.01
 Ticagrelor or prasugrel(%) 1.7 44.1 59.6 < 0.01
 Triple therapy (%) 16.1 12.1 8.8 < 0.01
 DAPT-duration (months ± SD) 2.5 ± 3 7.9 ± 5 10.9 ± 4 < 0.01
 DAPT-duration > 6 months (%) 8.9 58.2 89.2 < 0.01
 Statin (%) 71.4 66.1 65.6 0.11
 ACE-inhibitor/ATR (%) 55.6 56.7 55.1 0.88
 Betablocker (%) 70.4 61.9 59.6 < 0.01